News
Review: CAR-T therapy is being tested beyond cancer, but nothing is approved there yet
AI-assisted summary Written by WellCareChina with AI assistance and checked against the original article.
A review published in Signal Transduction and Targeted Therapy on 1 October 2026 surveys chimeric antigen receptor T-cell (CAR-T) therapy outside cancer, including autoimmune diseases, ageing-related conditions and infections. The authors describe how CAR-T cells have changed the treatment of some blood cancers and how researchers are now testing the same approach against disease-specific cell populations in conditions such as systemic lupus erythematosus. The review states that no CAR-T therapy has been approved for a non-oncological disease yet, that several clinical trials are under way, and that safety and manufacturing remain the main open questions.
Read the original article Opens the original source in a new tab.
Copyright and re-use
The original article is the authoritative text. This page carries our own summary and a link back; no part of the original is reproduced here.
Source tier A — open-access review (CC BY 4.0); our own summary and a link back to the original, no full-text copy.